Botanix Pharmaceuticals Limited
BXPHF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -1.98 | 0.27 | -0.01 |
| FCF Yield | -9.80% | -5.79% | -18.41% | -26.55% |
| EV / EBITDA | -9.49 | -26.95 | -10.46 | -3.54 |
| Quality | ||||
| ROIC | -76.14% | -14.22% | -59.31% | -271.29% |
| Gross Margin | 40.27% | -76.48% | -80.74% | -273.62% |
| Cash Conversion Ratio | – | 0.59 | 1.32 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.13% | -9.09% | -18.18% | -28.62% |
| Free Cash Flow Growth | -204.80% | -36.59% | -35.60% | -373.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 5.75 | 1.13 | 0.55 |
| Interest Coverage | -43.81 | -1,450.38 | -166.54 | -599.55 |
| Efficiency | ||||
| Inventory Turnover | 0.12 | 3.02 | 1.26 | 3.38 |
| Cash Conversion Cycle | 2,241.85 | -7.70 | 200.29 | -39.41 |